162 related articles for article (PubMed ID: 36645246)
1. A Comparison of FDA and EMA Pregnancy and Lactation Labeling.
Kappel D; Sahin L; Yao L; Thor S; Kweder S
Clin Pharmacol Ther; 2023 Jun; 113(6):1251-1257. PubMed ID: 36645246
[TBL] [Abstract][Full Text] [Related]
2. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Drug Labels Following the 2015 Pregnancy and Lactation Labeling Rule.
Byrne JJ; Saucedo AM; Spong CY
JAMA Netw Open; 2020 Aug; 3(8):e2015094. PubMed ID: 32865574
[TBL] [Abstract][Full Text] [Related]
4. Clinicians' Perspective of the New Pregnancy and Lactation Labeling Rule (PLLR): Results from an AAAAI/FDA Survey.
Namazy J; Chambers C; Sahin L; Johnson T; Dinatale M; Lappin B; Schatz M
J Allergy Clin Immunol Pract; 2020 Jun; 8(6):1947-1952. PubMed ID: 32084595
[TBL] [Abstract][Full Text] [Related]
5. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010).
DeMuro C; Clark M; Doward L; Evans E; Mordin M; Gnanasakthy A
Value Health; 2013 Dec; 16(8):1150-5. PubMed ID: 24326168
[TBL] [Abstract][Full Text] [Related]
6. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
[TBL] [Abstract][Full Text] [Related]
7. The Importance of Clinical Research in Pregnant Women to Inform Prescription Drug Labeling.
Dinatale M; Roca C; Sahin L; Johnson T; Mulugeta LY; Fletcher EP; Yao L
J Clin Pharmacol; 2020 Dec; 60 Suppl 2():S18-S25. PubMed ID: 33274508
[TBL] [Abstract][Full Text] [Related]
8. The Influence of the Food and Drug Administration Pregnancy and Lactation Labeling Rule on Drug Information Resources.
Harris JB; Holmes AP; Eiland LS
Ann Pharmacother; 2021 Apr; 55(4):459-465. PubMed ID: 32885981
[TBL] [Abstract][Full Text] [Related]
9. Availability of Safe and Effective Therapeutic Options to Pregnant and Lactating Individuals Following the United States Food and Drug Administration Pregnancy and Lactation Labeling Rule.
Patel A; Sushko K; Mazer-Amirshahi M; Pfuma Fletcher E; Fusch G; Chan O; Aghayi A; Chan AKC; Lacaze-Masmonteil T; Van Den Anker J; Samiee-Zafarghandy S
J Pediatr; 2023 Aug; 259():113342. PubMed ID: 36806753
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the US Food and Drug Administration Post-Marketing Commitments and Requirements for Pregnancy and Lactation.
Avachat C; Younis IR; Birnbaum AK
Clin Pharmacol Ther; 2023 Dec; 114(6):1238-1242. PubMed ID: 37750407
[TBL] [Abstract][Full Text] [Related]
11. The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.
Brucker MC; King TL
J Midwifery Womens Health; 2017 May; 62(3):308-316. PubMed ID: 28556499
[TBL] [Abstract][Full Text] [Related]
12. Clinical Lactation Studies of Neuropsychiatric Medications: Clinical Pharmacology and Labeling Considerations.
Nallani SC; Baisden K; Dinatale M; Basham L; Kwatra D; Yao L
J Clin Pharmacol; 2023 Jun; 63 Suppl 1():S159-S169. PubMed ID: 37317496
[TBL] [Abstract][Full Text] [Related]
13. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
14. Trends in pregnancy labeling and data quality for US-approved pharmaceuticals.
Mazer-Amirshahi M; Samiee-Zafarghandy S; Gray G; van den Anker JN
Am J Obstet Gynecol; 2014 Dec; 211(6):690.e1-11. PubMed ID: 24912093
[TBL] [Abstract][Full Text] [Related]
15. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
[TBL] [Abstract][Full Text] [Related]
16. Content and format of labeling for human prescription drug and biological products; requirements for pregnancy and lactation labeling. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2014 Dec; 79(233):72063-103. PubMed ID: 25509060
[TBL] [Abstract][Full Text] [Related]
17. Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006-2018).
Seo Y; Pacifici E
Vaccine; 2020 Nov; 38(47):7485-7489. PubMed ID: 33059971
[TBL] [Abstract][Full Text] [Related]
18. FDA's proposed rule for pregnancy and lactation labeling: improving maternal child health through well-informed medicine use.
Feibus KB
J Med Toxicol; 2008 Dec; 4(4):284-8. PubMed ID: 19031382
[TBL] [Abstract][Full Text] [Related]
19. Medication use in pregnancy and the pregnancy and lactation labeling rule.
Sahin L; Nallani SC; Tassinari MS
Clin Pharmacol Ther; 2016 Jul; 100(1):23-5. PubMed ID: 27082701
[TBL] [Abstract][Full Text] [Related]
20. FDA drug labeling for pregnancy and lactation drug safety monitoring systems.
Greene MF
Semin Perinatol; 2015 Nov; 39(7):520-3. PubMed ID: 26428020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
